Skip to main content
Premium Trial:

Request an Annual Quote

MRIGlobal, Evogen Enter MDx Product Development Pact

NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.

Under the terms of the non-exclusive deal, MRIGlobal is providing product development services to Evogen, which was spun out of MRIGlobal in 2002. Services being provided include assay development, technology transfer, analytical and clinical studies, and commercialization support.

Financial terms of the agreement were not disclosed.

Evogen develops PCR-based molecular diagnostic systems and is based in Lenexa, Kan.

MRIGlobal, previously called Midwest Research Institute, is a not-for-profit research institute and development organization. Its Diagnostics Division provides assay development for menu expansion in in vitro and molecular diagnostics, validation and clinical testing, and other services. It is headquartered in Kansas City, Mo.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.